The Alliance for Clinical Research Excellence and Safety (ACRES) announced the launch of ACRES BlueCloud™
The Alliance for Clinical Research Excellence and Safety (ACRES) announced the launch of ACRES BlueCloud™, the first phase implementation of a shared multi-user interface to allow sponsors, CROs, regulatory agencies, funding agencies and IRBs to access verifiable professional experience and training credentials, for sharing and mutual recognition credentials by multiple stakeholders.
The technology also provides a global integration platform through which stakeholders can access and deploy already established technology solutions and collaborative data warehouses to support a global system for high-performance Accountable Research™. ACRES’ strategic ally HealthCarePoint, a Texas-based healthcare and clinical research networking-technology corporation, provides the ACRES BlueCloud™capabilities. HealthCarePoint is among several technology companies and standards organizations comprising ACRES’ global Technology Consortium. Rollout of the ACRES Blue Cloud™ platform will begin immediately by providing the technology free of charge to clinical research sites worldwide, thereby extending and leveraging the existing global network of nearly three-quarter million current BlueCloud™ users from some 60,000 healthcare and research-related organizations worldwide. The network’s single sign-on interface will allow sites to connect with sponsors, CROs, ethics committees (IRBs) and other stakeholders through a unified platform, sharing critical professional and operational information, such as GCP training certifications and other professional credentials. As other provider technologies integrate with the shared platform through application programming interfaces, commonly known as APIs, additional functionality will be added.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
2 Commerce Drive
Cranbury, NJ 08512